Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645671 · ClinicalTrials.gov registry record · Phase 3
Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00645671 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 400 participants.
The verdict
NCT00645671, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery
Interventions
- DRUG 0.5% Loteprednol Etabonate Ophthalmic Ointment
- DRUG Vehicle of Loteprednol Etabonate Ophthalmic Ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645671
The ClinicalTrials.gov registry entry for NCT00645671 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 0.5% Loteprednol Etabonate Ophthalmic Ointment is the first listed.
NCT00645671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00645671 about?
NCT00645671 is a clinical study titled "Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery". To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery
What is the current status of trial NCT00645671?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2008-03. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00645671?
The interventions under investigation include: 0.5% Loteprednol Etabonate Ophthalmic Ointment (DRUG), Vehicle of Loteprednol Etabonate Ophthalmic Ointment (DRUG).
Who is sponsoring clinical trial NCT00645671?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.